Pacira BioSciences
PCRX
273 hedge funds and large institutions have $1.84B invested in Pacira BioSciences in 2022 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 95 increasing their positions, 93 reducing their positions, and 42 closing their positions.
10% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 42
2% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 93
0% more funds holding
Funds holding: 273 → 273 (0)
4% less ownership
Funds ownership: 109.57% → 105.57% (-4%)
31% less capital invested
Capital invested by funds: $2.67B → $1.84B (-$833M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
75% less call options, than puts
Call options by funds: $903K | Put options by funds: $3.58M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$33.3M |
| 2 |
AC
Armistice Capital
New York
|
+$14.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$10.6M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$7.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$43.6M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$23.9M |
| 3 |
SCM
Spyglass Capital Management
San Francisco,
California
|
-$18.7M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$14.3M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$13.1M |
PCRX Hedge Fund Activity: Q4 2022 in Review
273 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2022, worth a combined $1.84B — down 31% from $2.67B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new PCRX positions and 42 closed out — a net gain of 4 holders — while 95 added to existing stakes and 93 trimmed.
The largest buyer was Millennium Management, adding an estimated $33.3M. The largest seller was Macquarie Group, cutting an estimated $43.6M.
- 273 institutional investors held Pacira BioSciences (PCRX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $1.84B of Pacira BioSciences stock for Q4 2022, down 31% quarter-over-quarter.
- 46 funds opened new Pacira BioSciences positions in Q4 2022 and 42 closed out, a net change of +4 holders.
- The largest Pacira BioSciences buyer in Q4 2022 was Millennium Management, an estimated $33.3M added.
- The largest Pacira BioSciences seller in Q4 2022 was Macquarie Group, an estimated $43.6M sold.
Based on aggregated 13F filings for Q4 2022.